New hope for tough blood cancers: Four-Drug attack trial opens
NCT ID NCT04047641
Summary
This trial is testing whether adding a newer targeted drug (quizartinib) to a standard three-drug chemotherapy cocktail works better for controlling aggressive blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). It is for adults (18-65 for newly diagnosed, 18+ for relapsed) whose cancer is new, has come back, or hasn't responded to prior treatment. The main goals are to see if the combination is safe and effective at controlling the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.